<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014179</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1904</org_study_id>
    <nct_id>NCT04014179</nct_id>
  </id_info>
  <brief_title>Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs</brief_title>
  <acronym>TEMPO</acronym>
  <official_title>A Multi-centre, Practice-level, Stepped Wedge Cluster Randomized Controlled Trial to Compare Point-of-care HCV RNA Testing, Dried Blood Spot Testing, and Standard of Care to Enhance Treatment Uptake Among People With HCV Who Have Recently Injected Drugs Attending Needle and Syringe Programs: the TEMPO Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to evaluate two strategies of Hepatitis C virus (HCV) testing compared to&#xD;
      standard of care among people who inject drugs at needle and syringe program (NSP) services&#xD;
      in Australia, to see if it can improve the number of people who start treatment following an&#xD;
      HCV diagnosis:&#xD;
&#xD;
        1. HCV testing from collected dried blood spots sent to a central laboratory&#xD;
&#xD;
        2. HCV testing using a point-of-care device at the NSP site&#xD;
&#xD;
        3. HCV testing using standard of care at the NSP site&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TEMPO study will compare dried blood spot testing and point-of-care HCV RNA testing to&#xD;
      standard of care as strategies to enhance HCV treatment uptake among people with HCV and&#xD;
      recent injecting drug use attending NSP services. Peer support to enhance engagement and&#xD;
      facilitate linkage to nursing care will be provided in the intervention arms of this study.&#xD;
&#xD;
      The study is a stepped, wedge cluster randomized controlled trial. The sites (clusters) will&#xD;
      be primary NSPs which provide services to people who inject drugs and have capacity to&#xD;
      provide hepatitis C treatment services. The sites will be located in Australia.&#xD;
&#xD;
      Twenty-two NSPs (the clusters)* will be randomly allocated to receive the intervention&#xD;
      immediately (11 clusters) versus standard of care with delayed implementation (11 clusters).&#xD;
      The immediate intervention arm will be randomized 1:1 to receive point-of-care HCV RNA&#xD;
      testing (5 or 6 clusters)* or HCV RNA testing from dried blood spots (5 or 6 clusters)*. The&#xD;
      delayed intervention arm will have a period of standard of care (based on the number of&#xD;
      enrolled participants) and switch to receiving the intervention. The delayed intervention arm&#xD;
      will then be randomized 1:1 to receive point-of-care HCV RNA testing (5 or 6 clusters)* or&#xD;
      HCV RNA testing from dried blood spots (5 or 6 clusters)*. As such, at the end of the study,&#xD;
      there will be 11 clusters randomized to point-of-care HCV RNA testing or 11 clusters to HCV&#xD;
      RNA testing from dried blood spots.&#xD;
&#xD;
      *Based on randomisation, there will be 5 sites using point-of-care and 6 sites using dried&#xD;
      blood spots, or vice versa with 6 sites using point-of-care and 5 sites using dried blood&#xD;
      spots.&#xD;
&#xD;
      At screening, participants will be tested for HCV infection with dried blood spot,&#xD;
      point-of-care or standard of care, depending on cluster randomisation.&#xD;
&#xD;
      Screening in the intervention arm will continue until a total of 220 HCV RNA positive&#xD;
      participants (~20 participants per site) are enrolled in the intervention arm (either dried&#xD;
      blood spot and point-of-care). In the delayed intervention arm, 220 HCV RNA positive&#xD;
      participants (~20 participants per site) will be enrolled in the control (standard of care)&#xD;
      phase and then clusters/sites will be switched to intervention (either dried blood spot and&#xD;
      point-of-care) - at which screening will continue until a total of 220 HCV RNA positive&#xD;
      participants (~20 participants per site) are enrolled. Hence a total of 660 HCV RNA positive&#xD;
      participants.&#xD;
&#xD;
      HCV RNA negative participants will have no further assessments or visits as part of the study&#xD;
      protocol.&#xD;
&#xD;
      Participants who are HCV RNA positive will be enrolled in the follow-up cohort and will be&#xD;
      assessed for treatment eligibility. If eligible, they will be treated as per standard of care&#xD;
      with a pharmaceutical benefits scheme (PBS) approved pan-genotypic HCV DAA treatment.&#xD;
      Participants will be encouraged to take the first dose on the day of treatment work-up where&#xD;
      possible. On-treatment and post-treatment testing and monitoring will be based on the site&#xD;
      investigator as per standard clinical practice.&#xD;
&#xD;
      All HCV RNA positive participants will be followed up at 12 weeks, 24 weeks and 12 months&#xD;
      post enrolment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of HCV RNA positive who initiate HCV treatment</measure>
    <time_frame>12 weeks from Enrolment</time_frame>
    <description>To compare the proportion of HCV RNA positive participants who initiate HCV treatment at 12 weeks following enrolment between those who receive point-of-care HCV RNA testing, dried blood spot testing, and standard of care.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3300</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Immediate Intervention (Dried Blood Spot)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood samples will be tested for HCV RNA from dried blood spot cards.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate intervention (Point-of-care testing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood samples will be tested for HCV RNA using the Xpert HCV Viral Load Fingerstick point-of-care assay.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed intervention (Dried Blood Spot)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>There will be a period of business as usual, that is, sites will continue with standard of care for HCV RNA testing, then switch to intervention for HCV RNA testing from dried blood spots.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed intervention (Point-of-care testing)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>There will be a period of business as usual, that is, sites will continue with standard of care for HCV RNA testing, then switch to intervention for HCV RNA testing using the point-of-care assay.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Xpert HCV Viral Load Fingerstick</intervention_name>
    <description>The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is an in vitro nucleic acid amplification test designed for the quantitation of Hepatitis C Virus (HCV) DNA in human whole blood using the automated GeneXpert Systems. The HCV RNA result from the Xpert test will be used to initiate HCV treatment.</description>
    <arm_group_label>Delayed intervention (Point-of-care testing)</arm_group_label>
    <arm_group_label>Immediate intervention (Point-of-care testing)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Aptima HCV Quant DX Assay</intervention_name>
    <description>The Aptima HCV Quant Dx assay is a real-time transcription-mediated amplification test.&#xD;
The assay is used for both detection and quantitation of hepatitis C virus (HCV) RNA in fresh and frozen human serum and plasma from HCV-infected individuals, and in this study from dried blood spots. The HCV RNA result from the Aptima assay will be used to initiate HCV treatment.</description>
    <arm_group_label>Delayed intervention (Dried Blood Spot)</arm_group_label>
    <arm_group_label>Immediate Intervention (Dried Blood Spot)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for participants:&#xD;
&#xD;
        Attendees of the NSP service are eligible for inclusion if the following criteria are met:&#xD;
&#xD;
          1. Provided written informed consent&#xD;
&#xD;
          2. â‰¥ 18 years of age&#xD;
&#xD;
          3. Recent injecting drug use - defined as self-reported use within the previous six&#xD;
             months.&#xD;
&#xD;
        Exclusion criteria for participants:&#xD;
&#xD;
        a. Is unable or unwilling to provide informed consent or abide by the requirements of the&#xD;
        study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elise Tu, PhD</last_name>
    <phone>61-2-9385-9000</phone>
    <email>etu@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>NSP Civic</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Stephanie Stephens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bankstown NSP</name>
      <address>
        <city>Bankstown</city>
        <state>New South Wales</state>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Gilbert Whitton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WSLHD Drug Health - Blacktown NSP</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Thao Lam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NSP Phillip</name>
      <address>
        <city>Canberra</city>
        <state>New South Wales</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Stephanie Stephens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coffs Harbour Primary NSP</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Franklin John Leader</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gosford NSP</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Amanda Burfitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kempsey Primary NSP</name>
      <address>
        <city>Kempsey</city>
        <state>New South Wales</state>
        <zip>2440</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Franklin John Leader</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lismore Primary NSP</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Franklin John Leader</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Southwest NSP</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Gilbert Whitton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WSLHD Drug Health - Mt Druitt NSP</name>
      <address>
        <city>Mount Druitt</city>
        <state>New South Wales</state>
        <zip>2770</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Thao Lam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tweed Primary NSP</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Franklin John Leader</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orana Centre</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>David Reid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alcohol and Drug Harm Reduction Biala</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jeremy Hayllar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severin Street NSP</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Carla Gorton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inala</name>
      <address>
        <city>Inala</city>
        <state>Queensland</state>
        <zip>4077</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Ali Carrim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kobi House</name>
      <address>
        <city>Toowoomba</city>
        <state>Queensland</state>
        <zip>4350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Matthew Ruhl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Adelaide</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Morgyn Warner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonggangga Turtpandi Aboriginal Primary Health Care Services</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5015</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Morgyn Warner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern DASSA</name>
      <address>
        <city>Elizabeth</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Damien Harding</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Noarlunga Health Precinct</name>
      <address>
        <city>Noarlunga</city>
        <state>South Australia</state>
        <zip>5168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Alan Wigg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peer Based Harm Reduction Bunbury</name>
      <address>
        <city>Bunbury</city>
        <state>Western Australia</state>
        <zip>6230</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Leanne Myers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peer Based Harm Reduction Perth</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <investigator>
      <last_name>Leanne Myers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 7, 2019</study_first_submitted>
  <study_first_submitted_qc>July 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus, Needle and Syringe Programs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

